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An expanded hexanucleotide repeat in the C9ORF72 gene has recently been identiﬁed as a major cause of familial frontotem-
poral lobar degeneration and motor neuron disease, including cases previously identiﬁed as linked to chromosome 9. Here we
present a detailed retrospective clinical, neuroimaging and histopathological analysis of a C9ORF72 mutation case series in
relation to other forms of genetically determined frontotemporal lobar degeneration ascertained at a specialist centre. Eighteen
probands (19 cases in total) were identiﬁed, representing 35% of frontotemporal lobar degeneration cases with identiﬁed
mutations, 36% of cases with clinical evidence of motor neuron disease and 7% of the entire cohort. Thirty-three per cent
of these C9ORF72 cases had no identiﬁed relevant family history. Families showed wide variation in clinical onset (43–68 years)
and duration (1.7–22 years). The most common presenting syndrome (comprising a half of cases) was behavioural variant
frontotemporal dementia, however, there was substantial clinical heterogeneity across the C9ORF72 mutation cohort. Sixty
per cent of cases developed clinical features consistent with motor neuron disease during the period of follow-up. Anxiety and
agitation and memory impairment were prominent features (between a half to two-thirds of cases), and dominant parietal
dysfunction was also frequent. Affected individuals showed variable magnetic resonance imaging ﬁndings; however, relative to
healthy controls, the group as a whole showed extensive thinning of frontal, temporal and parietal cortices, subcortical grey
matter atrophy including thalamus and cerebellum and involvement of long intrahemispheric, commissural and corticospinal
tracts. The neuroimaging proﬁle of the C9ORF72 expansion was signiﬁcantly more symmetrical than progranulin mutations with
signiﬁcantly less temporal lobe involvement than microtubule-associated protein tau mutations. Neuropathological examination
in six cases with C9ORF72 mutation from the frontotemporal lobar degeneration series identiﬁed histomorphological features
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DNA-binding protein-43 positive) neuronal cytoplasmic inclusions in hippocampus and cerebellum were a consistent feature
of these cases, in contrast to the similar frequency of p62 and TAR DNA-binding protein-43 deposition in 53 control cases with
frontotemporal lobar degeneration–TAR DNA-binding protein. These ﬁndings corroborate the clinical importance of the
C9ORF72 mutation in frontotemporal lobar degeneration, delineate phenotypic and neuropathological features that could
help to guide genetic testing, and suggest hypotheses for elucidating the neurobiology of a culprit subcortical network.
Keywords: frontotemporal lobar degeneration; motor neuron disease; neurodegenerative disorders; neuroimaging; genetics
Abbreviations: FTD = frontotemporal dementia; FTLD = frontotemporal lobar degeneration; MND = motor neuron disease;
TDP = TAR DNA-binding protein
Introduction
The frontotemporal lobar degenerations (FTLD) are a common
cause of young onset neurodegeneration (Ratnavalli et al.,
2002). FTLD is clinically and pathologically heterogeneous (Lillo
et al., 2010; Seelaar et al., 2011) and genetic factors play a sig-
niﬁcant role, with a genetic basis implicated in up to 40% of cases
in series from specialist centres (Rohrer et al., 2009; Rohrer and
Warren, 2011). Discovery of disease-causing mutations in the pro-
granulin (GRN) and microtubulin-associated protein tau (MAPT)
genes left a substantial minority of cases of autosomal dominant
FTLD without an identiﬁed genetic substrate; however, linkage to
chromosome 9p21 has been described in a number of families
with phenotypes of frontotemporal dementia (FTD), motor
neuron disease (MND) or overlap syndrome (Morita et al.,
2006; Vance et al., 2006; Valdmanis et al., 2007; Luty et al.,
2008; Le Ber et al., 2009; Gijselinck et al., 2010; Boxer
et al., 2011; Pearson et al., 2011). This elusive chromosome
9 gene has recently been identiﬁed as an expanded hexanucleo-
tide (GGGGCC) repeat insertion in a non-coding promoter region
of open reading frame 72 (C9ORF72) and is likely to account for a
substantial proportion of the remaining genetic susceptibility to
FTLD and MND) (Dejesus-Hernandez et al., 2011; Gijselinck
et al., 2011; Renton et al., 2011). Cases with the C9ORF72
repeat expansion with histopathological correlation have had
TAR DNA-binding protein (TDP)-43 deposition, however, the
pathogenic mechanism whereby the expansion leads to neurode-
generation has not been deﬁned.
As has been demonstrated previously in the case of MAPT and
GRN-associated FTLD (Rademakers et al., 2007; Beck et al., 2008;
Le Ber et al., 2008; Rohrer and Warren, 2011) detailed phenotypic
characterization of disease-causing mutations has both clinical and
neurobiological implications. Clinically, such a characterization will
help guide genetic screening and thereby facilitate early, accurate
diagnosis, and ultimately the possibility of identifying individuals
both with established and incipient disease for clinical trials of
disease-modifying therapies. Neurobiologically, phenotypic infor-
mation may help elucidate the pathophysiology of the disease,
for example, by delineating the interaction of the molecular
lesion with affected neural networks (Fletcher and Warren,
2011; Rohrer et al., 2011). Here we describe the clinical, neuro-
psychological, neuroimaging and neuropathological features of
a large series of cases with the C9ORF72 hexanucleotide repeat
expansion ascertained at a tertiary referral centre.
Subjects and methods
Case ascertainment
The University College London FTLD DNA cohort comprises 273
cases (256 probands) with a syndromic diagnosis within the FTLD
spectrum (Litvan et al., 1996; Boeve et al., 2003; Gorno-Tempini
et al., 2011; Rascovsky et al., 2011), including 122 patients with
behavioural variant FTD, 11 patients with FTD and MND (FTD–
MND), 53 patients with semantic dementia, 49 patients with
progressive non-ﬂuent aphasia, 18 patients with corticobasal
syndrome, eight patients with a progressive non-ﬂuent aphasia–
corticobasal overlap syndrome, 11 patients with progressive supra-
nuclear palsy syndrome and one patient with the inclusion body
myopathy–Paget’s disease–frontal dementia syndrome. DNA is
also held on a further 11 patients with the logopenic aphasia
variant of primary progressive aphasia (Gorno-Tempini et al.,
2011). The cohort includes 22 cases with MAPT mutations (15
probands), 24 cases with GRN mutations (17 probands) and one
case with a valosin-containing protein (VCP) mutation (Table 1).
Thus, 223 probands with FTLD syndromes and 11 individuals with
logopenic aphasia lacking a previously identiﬁed pathogenic mu-
tation were included in the present screen for the C9ORF72
repeat expansion. Prior to screening, all cases within the cohort
were assigned a modiﬁed Goldman score as a measure of the
extent of family history of the disease (Goldman et al., 2005;
Beck et al., 2008; Rohrer et al., 2009). A score of 1 represents
an autosomal dominant family history of FTLD or MND; 2 is fa-
milial aggregation of three or more family members with demen-
tia; 3 is one other ﬁrst-degree relative with dementia of young
onset (565 years); 3.5 is one other ﬁrst-degree relative with de-
mentia of onset 465 years of age; and 4 is no or unknown family
history. Of the probands with a diagnosis within the FTLD spec-
trum included in the screen, six had a Goldman score of 1; 26 had
a score of 2; 12 had a score of 3; 22 had a score of 3.5; and 157
had a score of 4 (Table 1).
Ethical approval for the study was obtained from the local in-
stitutional ethics committee and carried out in accordance with the
Declaration of Helsinki.
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All samples with genetically unexplained FTLD based on previous
screens were assessed for C9ORF72 expansions using the
repeat-primed polymerase chain reaction as previously published
(Renton et al., 2011). Mutations were called if repeats of this
assay consistently showed more than 30 repeats in total (Fig. 1).
Clinical and neuropsychological
analyses
A retrospective review of clinical case notes and neuropsychologic-
al reports (where available) was undertaken in those cases identi-
ﬁed as having the C9ORF72 repeat expansion. Demographic
features, family history and disease duration were recorded.
Earliest clinical features were extracted by an experienced neur-
ologist, and neuropsychological features at ﬁrst assessment were
also recorded; 13 participants had undergone more than one clin-
ical assessment, and clinical features at the ﬁnal assessment were
also recorded. Demographic data for C9ORF72 cases were com-
pared statistically with MAPT and GRN mutation groups using
two-tailed t-tests within STATA 10 (Statacorp).
In addition, we recorded results of laboratory investigations
undertaken as part of the clinical evaluation of C9ORF72 cases:
electrophysiological assessments and CSF examination [including
Ab1–42 level (Innotest b-amyloid1–42, Innogenetics), total tau
(Innotest hTau Ag, Innogenetics) and S100 beta (Abnova)].
Neuroimaging analyses
A majority of patients included in the University College London
FTLD cohort have had at least one T1-weighted magnetic reson-
ance brain volume acquired on either a 1.5T GE Signa scanner
(General Electric) (256  256 matrix; 1.5cm slice thickness) or a
3.0T Siemens Trio scanner (Siemens) (256  256 matrix; 1.1cm
slice thickness). Where available, volumetric brain MRI data for
the C9ORF72 mutation cases were analysed using previously
described semi-automated techniques and compared with the
GRN and MAPT mutation groups.
Figure 1 Examples of electrophoresed products of repeat-primed polymerase chain reaction used to detect expansions in C9ORF72. Each
panel was scaled to 800 ﬂuorescent units on the y-axis and between 300–650bp on the x-axis. (A) Data from a FTLD patient sample
without an expansion and (B) data from a patient with FTLD with 2 and 460 repeats.
Table 1 Numerical data on mutation frequency, demographics and family history for cases in this series
n (% total) per modiﬁed Goldman score
Group n Male (%) AAO (SD) Probands (% totals) 1 (%) 2 (%) 3 (%) 3.5 (%) 4 (%)
C9ORF72 19 58 55.1 (6.6) 18 (7.0) 4 (23.5) 6 (17.6) 1 (5.6) 1 (4.2) 6 (3.7)
MAPT 22 59 51.7 (6.9) 15 (5.9) 6 (35.3) 3 (8.8) 3 (16.7) 1 (4.2) 2 (1.2)
GRN 24 50 57.6 (6.5) 17 (6.6) 4 (23.5) 5 (14.7) 3 (16.7) 1 (4.2) 4 (2.5)
VCP 1 100 44.0 1 (0.4) 1 (5.9) 0 0 0 0
Others 207 57 59.0 (8.6) 205 (80.1) 2 (11.8) 20 (58.8) 11 (61.1) 21 (87.5) 151 (92.6)
Total 273 256 17 34 18 24 163
In summary, if the modiﬁed Goldman score is 1, 88% of patients have a known genetic abnormality, and this percentage decreases with a higher score: 41% if the score is
2, 39% if the score is 3, 13% if the score is 3.5 and 7% if the score is 4. AAO = age at onset.
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rated from CSF, dura and skull (Freeborough et al., 1997). Scans
were then transformed into standard space by registration to the
Montreal Neurological Institute template and hemispheric volumes
were calculated for each individual. In order to assess hemispheric
asymmetry, a left/right asymmetry ratio was derived in each case
by dividing the left hemispheric volume by the right hemispheric
volume, as previously described (Rohrer et al., 2010). Repeat
scans were transformed into standard space and underwent an
afﬁne registration (12 degrees of freedom) onto the baseline
scan. Volume change was calculated directly from registered
scans using the brain boundary shift integral (Freeborough and
Fox, 1997). Brain boundary shift integral-derived whole-brain
volume changes were expressed as an annualized volume
change in ml per year. Volumetric data from a previously pub-
lished cohort (Rohrer et al., 2010) of GRN [n = 4, mean interval
1.3 years, standard deviation (SD) 0.2] and MAPT (n = 6, 2.1
years, SD 1.0) mutation carriers (all values derived using the
same methods) were compared against C9ORF72 mutation car-
riers using two-sample t-tests with unequal variance within STATA
10 (Statacorp).
In order to determine patterns of brain atrophy at group level,
volumetric MRI data from healthy controls and the C9ORF72,
MAPT and GRN mutation groups were compared using
voxel-based morphometry with the DARTEL toolbox of SPM8
(http://www.ﬁl.ion.ucl.ac.uk/spm) running under Matlab 7.0
(Mathworks). Segmentation, modulation and smoothing of grey
and white matter images were performed using default parameter
settings. Final images were normalized to standard space. In order
to reduce the effects of atrophy, analysis was performed over
voxels within a consensus mask, which includes all voxels with
intensity of 40.1 in 70% of subjects (Ridgway et al., 2009). A
multiple regression analysis was performed with voxel intensity
modelled as a function of group membership with age, total intra-
cranial volume, gender and scanner ﬁeld strength included as nuis-
ance covariates. Results were then overlaid on the MNI152
template brain for anatomical analysis. Total intracranial volume
was calculated by summing together grey matter, white matter
and CSF segmentations.
Cortical thickness measurements were made using FreeSurfer
v5.1 (http://surfer.nmr.mgh.harvard.edu/) following previously
described methods (Dale et al., 1999; Fischl and Dale, 2000). A
surface-based Gaussian smoothing kernel of 20mm full width at
half-maximum was applied to reduce local variations in cortical
thickness. Skull stripping used a locally generated brain mask,
and FreeSurfer ventricular segmentations were added to the
white matter mask to improve cortical segmentation. Between-
group variations in cortical thickness were assessed using a
vertex-by-vertex general linear model performed with SurfStat
(http://www.math.mcgill.ca/keith/surfstat/). Regional differences
in grey matter between control and disease groups were assessed
using the same covariates as the voxel-based morphometry ana-
lysis. A signiﬁcance threshold of P50.05 with false discovery rate
correction was applied. Where this threshold was not met, per-
centage difference maps were used to illustrate trends in atrophy
patterns.
Alterations of white matter tract integrity were assessed with
diffusion tensor imaging using an unbiased group-wise analysis
technique. Three individuals underwent diffusion tensor imaging
scanning on the same 3T scanner (64 direction single shot, spin-
echo-echo planar imaging sequence, 55 contiguous slices). Tensor
eigenvalues (1 = axial diffusivity, 2 and 3), fractional anisot-
ropy and radial diffusivity (RD = 2+3) were extracted at each
voxel using CAMINO (Cook et al., 2006). Tensor ﬁtted images
were then imported for voxel-wise analysis within tract-based spa-
tial statistic (TBSS v1.1) (Smith et al., 2006). Voxel intensity within
tracts was modelled on disease group membership with the age,
gender and total intracranial volume included as nuisance covari-
ates. Statistical analysis was implemented using the permutation-
based (non-parametric) randomize tool within FSL.
For all group-wise analyses, a signiﬁcance threshold (P50.05)
was applied following correction for multiple comparisons.
Threshold-free cluster enhancement modulation was applied to
diffusion tensor imaging results (Smith and Nichols, 2009).
Neuropathological protocol
Cases in the University College London FTLD cohort coming to
post-mortem have undergone detailed histopathological assess-
ment as previously described (Lashley et al., 2011; Rohrer et al.,
2011). At the time of brain donation, brains were ﬁxed in 10%
buffered formaldehyde and sampled using standard protocols.
Histological sections of hippocampus with parahippocampal and
fusiform gyri and cerebellum, stained with antibodies to p62
(1:200, BD Transduction Laboratories) and TDP-43 (amino acids
1-261, Abnova, 1:800), were analysed. Selection of these anatom-
ical regions was based on preliminary observations indicating that
the number of p62-positive inclusions may exceed
TDP-43-positive neuronal cytoplasmic inclusions in C9ORF72 mu-
tation cases; using a semi-quantitative approach, the frequency of
p62-positive neuronal cytoplasmic inclusions was compared with
TDP-43-positive inclusions in the granule cell layer of the dentate
fascia, hippocampal subregions and cerebellar granule cell layer.
Results
Genetics
Of the 223 cases with FTLD screened, 18 probands (8% of pro-
bands without previously identiﬁed mutations) were found to have
the C9ORF72 repeat expansion. One further case in the cohort,
from the same family as one of the probands, also had the
C9ORF72 expansion. No mutations were identiﬁed in the 11
screened cases with logopenic aphasia. Alternatively expressed,
18/51 (35%) of all FTLD probands with identiﬁed mutations or
18/256 (7%) of all probands in our FTLD series had a C9ORF72
mutation. Of the 18 C9ORF72 probands, four patients had a
modiﬁed Goldman score of 1, six had a score of 2, one had a
score of 3, one had a score of 3.5 and six had a score of 4 (Fig. 2
and Table 1), indicating that in this series 6/163 (4%) of appar-
ently sporadic cases of FTLD had a C9ORF72 mutation. If an
individual had a Goldman score of 1 assigned, a genetic cause
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of all FTLD probands, of which 35% were MAPT, 24% were
C9ORF72, 24% were GRN and 6% were VCP mutations. If a
score of 2 was assigned, a genetic cause was identiﬁed in 41%
of cases; if a score of 3 was assigned, a genetic cause was identi-
ﬁed in 39%; if a score of 3.5 was identiﬁed, a genetic cause was
identiﬁed in 13% and if a score of 4 was assigned, a genetic cause
was identiﬁed in 7% of cases. Representative pedigrees of
C9ORF72 families are shown in Fig. 3. The pedigree data indicate
that age at symptom onset and clinical syndrome are highly vari-
able within a family.
Clinical and neuropsychological
features
The average age at onset across the series was 55.0 years (SD 6.6,
range 43–68), which did not differ signiﬁcantly from MAPT or
GRN mutation groups. Mean disease duration from symptom
onset until death (n = 12) or time of last review (still alive n =5 )
was 8.7 years (SD 4.9, range 1.7–22), which was not signiﬁcantly
different to either the MAPT mutation group (11.4 SD 5.3 years)
or the GRN mutation group (6.8 SD 2.3 years). As a proportion of
the entire FTLD cohort, 11% of cases with behavioural variant
FTD, 36% with FTD–MND and 2% with progressive non-ﬂuent
aphasia were found to have the C9ORF72 repeat expansion.
Detailed clinical information was available on 16 of the 19 cases
with the C9ORF72 expansion who had been assessed in the
specialist cognitive disorders clinic at the National Hospital for
Neurology and Neurosurgery. Fifteen patients had neuropsycho-
logical assessments. Group data for these cases are summarized in
Fig. 4 and individual data in Table 2. The mean duration of
follow-up was 2.3 (SD 1.4) years. At initial presentation, eight
of these 16 patients (50% of cases) had a clinical syndromic diag-
nosis of behavioural variant FTD; three (19%) had a diagnosis of
FTD–MND; two (13%) had a diagnosis of probable Alzheimer’s
disease; one had a diagnosis of progressive non-ﬂuent aphasia,
one an encephalitic illness and one atypical Parkinsonism.
The ﬁnal syndromic diagnoses were behavioural variant FTD in
12 cases, FTD–MND in three cases and progressive non-ﬂuent
Figure 3 Representative pedigrees from the Dementia Research Centre (DRC) cohort indicating inheritance, predominant clinical
syndrome and, where known, age at onset (RIP indicates only age at death known). bvFTD = behavioural variant FTD.
Figure 2 FTLD DNA cohort by modiﬁed Goldman score.
Each bar displays % of cohort by assigned Goldman score and
mutation status.
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for ﬁrst and ﬁnal assessments are coded separately.
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Case Final
diagnosis
AAO
(years)
Duration
(years)
Hand Early symptoms Neuropsychology proﬁle
VIQ PIQ RMTW
a RMTF
a GNT
a Calc
a Percep
a Exec Praxis
1 bvFTD 51 6.0 R Anxiety, disinhibition,
episodic memory impair-
ment, speech adynamic
80 89 55 51 50–75 51 45 + + Norm
2 bvFTD 60 7.0
b R Anxiety, delusions, disin-
hibition, episodic memory
impairment, hyperorality
100 113 5–10 559 5550 45 + + Norm
3 bvFTD 56 8.0
b Anxiety, empathy loss,
obsessionality,
prosopagnosia
82 77 55 10–25 55 5–10 45 + + Imp
4 FTD–MND 55 7.7 Disinhibition, obsessionality,
speech effortful, weak-
ness upper limbs
Norm
5 bvFTD 45 8.4 L Anxiety, apathy, depres-
sion, involuntary
movements
71 75 55 55 55 45+ +
6 bvFTD 55 7.1 Disorganization, episodic
memory impairment,
obsessionality
87 78 55 51 55 5–10 45 + + Imp
7 bvFTD 55 16.6 Disorganization, empathy
loss, episodic memory
impairment,
prosopagnosia
103 95 50–75 51 75 25–50 45+ +
8 bvFTD 43 1.7 R Anxiety, apathy, disinhib-
ition, prosopagnosia,
topographical memory
impairment
UT UT UT UT 5 55 45 + Imp
9 FTD–MND 64 5.4 R Apathy, delusions, proso-
pagnosia, speech effort-
ful, topographical
memory impairment
84 82 5–10 51 55 55 45 + + Norm
10 FTD–MND 54 5.0 R Depression, disinhibition,
speech effortful,
weakness limbs
69 80 5–10 1–5 10–25 55 45 + Imp
11 bvFTD 58 8.0
b R Apathy, disinhibition,
hyperorality, topograph-
ical memory impairment
85 69 10–25 50–75 10–25 550 45 +++ I m p
12 bvFTD 61 5.7 R Episodic memory impair-
ment, hyperorality, falls,
somatic symptoms,
weakness limbs
78 76 51 51 55 10–25 45 +++ I m p
13 bvFTD 68 7.1 R Apathy, episodic and topo-
graphical memory impair-
ment, speech adynamic
73 78 55 55 10–25 10–25 45 + + Imp
14 bvFTD 53 14.8 Apathy, disinhibition,
episodic memory
impairment,
prosopagnosia
UT UT 55 55 51U T 45 + Imp
15 PNFA 55 5.0
b R Comprehension
impairment, disinhibition,
speech effortful
55 70 25–50 51 55 51 45 + + + Norm
16 bvFTD 46 22.0
b R Anxiety, disorganization,
episodic memory
impairment,
obsessionality,
prosopagnosia
116 113 75–95 50–75 75–90 490 45 + + Norm
Blank cells indicate testing not performed.
a Percentile scores are shown.
b Current duration for living cases.
+/+ +/+ + + = defective performance on at least one/two/three tests, respectively, of executive function (Weigl sorting test; Wisconsin Card Sorting Test; Stroop colour
interference; Verbal Fluency).
AAO = age at onset; bvFTD = behavioural variant FTD; Calc = calculation; Dur = total/current disease duration; Exec = executive functions; GNT = Graded Naming Test;
Hand = handedness data available; Imp = impaired; Norm = normal; Percep = perception; PIQ = performance IQ; PNFA = progressive non-ﬂuent aphasia; RMTF/
W = recognition memory test for faces/words; UT = untestable; VIQ = verbal IQ.
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tailed clinical information, the ﬁnal diagnoses were behavioural
variant FTD in two cases and FTD–MND in one case.
The most common symptoms at the time of ﬁrst presentation
(Fig. 4) were disinhibition (63%) and apathy (49%); however,
forgetfulness (44%) and anxiety (38%) were also prominent.
Based on the history obtained from patients’ carers, the most
common initial symptom was anxiety (33%), followed by disinhib-
ition (13%), effortful speech (13%) and impaired topographical
memory (13%). At the time of ﬁnal assessment, the most frequent
symptoms were disinhibition (76%), apathy/adynamia (63%), and
anxiety (52%). The most common neuropsychological features
(Table 2) were executive dysfunction (100%), impaired verbal
and/or visual episodic memory (87%), apraxia (57%), anomia
(47%) and dyscalculia (38%). Object and space perception were
unimpaired in all patients assessed. The most common physical
neurological sign at presentation was brisk deep tendon reﬂexes
(40%); fewer than 20% of patients had features of bulbar or
lower motor neuron involvement. At the time of ﬁnal assessment
(or ﬁrst if only one assessment), the most frequent neurological
signs were brisk tendon reﬂexes (60%), spasticity (47%), fascicu-
lations (33%) and primitive reﬂexes (33%).
Four patients (two with an initial clinical diagnosis of FTD–
MND) underwent electrophysiological studies; one individual had
EMG evidence of MND, one had borderline features and two had
no features of MND. Five patients underwent CSF examination.
Basic CSF constituents including protein, cells and glucose were
within normal limits for all patients examined; further analyses
comprised Ab1–42 (mean = 465pg/ml, SD 303, in-house normal
range = 220–2000; all within the normal range), total tau
(mean = 190pg/ml, SD 103, in-house normal range = 0–32;
80% of cases within the normal range) and S100 beta
(mean = 0.33ng/ml, SD 0.1, in-house normal range = 0.05–0.61;
all within the normal range). The mean tau-to-beta-amyloid ratio
was 0.5 (SD 0.3) and also within the normal limits for the assaying
laboratory for all subjects.
Neuroimaging features
Volumetric data
Eleven patients with the C9ORF72 repeat expansion (mean age
58.5, SD 8.3 years) underwent volumetric brain MRI: eight at 1.5T
and three at 3.0T. Five patients had repeat volumetric MRI on the
same scanner (mean interval 1.2 years, SD 0.6), four at 1.5T and
one at 3T. Inspection of individual brain magnetic resonance scans
revealed highly variable proﬁles of frontal, temporal and parietal
lobe atrophy; representative sections are shown in Fig. 5.
For the purposes of the group-wise analysis, neuroimaging data
from the C9ORF72 mutation group were compared with a group
of 15 age- and gender-matched healthy control subjects (mean
age 58.6, SD 5.7 years); brain images were acquired for 12 con-
trols on the same 1.5T magnetic resonance scanner and for three
controls on the same 3T scanner as the patients, and all
group-wise analyses were adjusted for variation in ﬁeld strength.
Mean brain volume corrected for total intracranial volume was
signiﬁcantly lower in the C9ORF72 mutation group (Fig. 6)
(mean brain/total intracranial volume ratio = 0.68, SD 0.07;
P = 0.001) than the control group (mean brain/total intracranial
volume = 0.77, SD 0.03); mean brain volume did not differ sig-
niﬁcantly between the C9ORF72 mutation group and the MAPT
or PGRN mutation groups. Mean annualized atrophy rate was
greatest in the GRN mutation group (Fig. 6) (brain boundary
shift integral change 3.4%/year, SD 0.6) followed by the
C9ORF72 mutation group (brain boundary shift integral change
1.6%/year, SD 1.6) and the MAPT mutation group (brain bound-
ary shift integral change 1.4%, SD 0.6), but mean atrophy rates
did not differ signiﬁcantly between groups. As indexed using the
hemispheric asymmetry ratio, cerebral atrophy was relatively sym-
metric in the C9ORF72 mutation group (Fig. 6) (hemispheric
asymmetry ratio range 0.96–1.04) and the MAPT mutation
group (range 0.97–1.05), similar to the healthy control group
(range 0.98–1.02); whereas cerebral atrophy was strongly asym-
metric in the GRN mutation group (range 0.86–1.33).
Unbiased analyses
In the voxel-based morphometry analysis, relative to the healthy
control group (n = 15), the C9ORF72 mutation group (n = 11)
showed a regional proﬁle of grey matter atrophy including thal-
amus bilaterally, left opercular cortex, left orbitofrontal cortex and
bilateral posterior cerebellum (all false discovery rate corrected
P50.05; Fig. 7). Direct comparisons between the C9ORF72 mu-
tation group and the MAPT mutation group (n = 11) (Fig. 8)
showed the MAPT group had decreased grey matter bilaterally
in anterior temporal lobe, amygdala, hippocampus and parahippo-
campal gyrus (all false discovery rate corrected P50.05), while
the C9ORF72 group had decreased grey matter in prefrontal
cortex and cerebellar vermis (uncorrected P50.001). Direct com-
parisons between the C9ORF72 mutation group and the GRN
mutation group (n = 8) (Fig. 8) showed that the GRN group had
decreased grey matter asymmetrically in left inferior and middle
temporal gyri, post-central gyrus and inferior frontal gyrus, where-
as the C9ORF72 group had decreased grey matter in right pre-
frontal cortex (all uncorrected P50.001).
In the cortical thickness analyses, relative to healthy controls,
the C9ORF72 mutation group showed a symmetrical pattern of
reduced thickness of frontal, anterior and superior temporal and
parietal cortices (Fig. 7). Direct comparisons between the
C9ORF72 and MAPT mutation groups showed the MAPT group
had reduced thickness of anterior temporal cortex bilaterally (false
discovery rate corrected P50.05) (Fig. 8). Direct comparisons
between the C9ORF72 and GRN mutation groups showed the
GRN group had asymmetrically reduced thickness of left inferior
frontal, temporal and parietal cortices, whereas the C9ORF72
group had reduced thickness of right dorsal frontal, temporal
and parietal cortices (Fig. 8).
In the diffusion tensor imaging analysis (Fig. 7), relative to
healthy controls, the cases with C9ORF72 mutation showed
increased radial diffusivity and decreased fractional anisotropy
bilaterally in anterior thalamic radiations, uncinate fasciculus, an-
terior cingulum and anterior corpus callosum; and in right posterior
corpus callosum, posterior inferior longitudinal fasciculus and
superior longitudinal fasciculus (all family-wise error corrected
P50.05). In addition, the C9ORF72 cases showed increased
The phenotype of C9ORF72 Brain 2012: 135; 736–750 | 743radial diffusivity in left frontal superior longitudinal fasciculus and
posterior corpus callosum, and in the right corticospinal tract.
Histopathological features
Genetic studies of the neuropathological FTLD cohort identiﬁed six
cases with the C9ORF72 repeat expansion. These cases were as-
sessed in relation to a group of 53 ‘control’ cases with FTLD-TDP
[four cases with type B TDP-43 pathology (Mackenzie et al.,
2011), 11 type A cases with a GRN mutation, 17 type A cases
without a GRN mutation and 21 type C cases]. TDP-43 pathology
was evident in the hippocampus in all cases with FTLD-TDP irre-
spective of the presence of the C9ORF72 repeat expansion. Four
of the six cases with C9ORF72 mutation were previously classiﬁed
as FTLD-TDP type A while two cases had type B pathology. All six
cases contained sparse to moderate numbers of compact and/or
‘star-shaped’ neuronal cytoplasmic inclusions in the granule cell
layer of the hippocampal dentate gyrus. Sparse TDP-43-positive
neuronal cytoplasmic inclusions were also found in the CA4 to
CA1 hippocampal subregions with two cases also containing an
Figure 5 Representative T1-weighted coronal magnetic resonance brain images for cases with C9ORF72 mutation. Numbering of cases
is as per Table 2. Patterns of atrophy were highly variable across the group, and no clear consistent proﬁle of atrophy was evident visually.
The distribution of atrophy was not prominently asymmetric between the cerebral hemispheres in most cases. Several cases had
predominantly frontal lobe atrophy (Cases 1, 2 and 13), while temporal lobe atrophy was prominent in other cases (Cases 6 and 9).
Other cases showed more generalized involvement with more prominent central atrophy (Cases 8 and 15) or minimal cross-sectional
atrophy to visual inspection (Case 16).
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TDP-43-positive neurites were also seen. No TDP-43 pathology
was observed in the cerebellum of either the cases with
C9ORF72 mutation or FTLD-TDP controls.
All six cases with C9ORF72 mutation contained p62-positive
small, ‘star-shaped’ neuronal cytoplasmic inclusions in the granule
cells of the hippocampal dentate gyrus. The numbers of such
inclusions ranged from moderate to frequent where virtually all
neurons contained neuronal cytoplasmic inclusions (Fig. 9) and
similar p62-positive neuronal cytoplasmic inclusions were also
found in variable numbers throughout the hippocampus from
the CA4 to the CA1 subregions. P62 immunohistochemistry also
highlighted neuritic structures. In all cases with C9ORF72 muta-
tion, p62-positive inclusions were strikingly more frequent than
TDP-43-positive inclusions (Fig. 9A and B). In the control
FTLD-TDP cases, the number of the p62-positive neuronal cyto-
plasmic inclusions in the hippocampal neurons including the gran-
ule cells of the dentate gyrus mirrored the frequency of TDP-43
immunoreactive neuronal cytoplasmic inclusions.
Small, p62-positive, but TDP-43-negative neuronal cytoplasmic
inclusions were found in the cytoplasm of the cerebellar granule
cells in all cases with C9ORF72 mutation, but not in the control
cases. The severity of the cerebellar pathology ranged from rare
p62-positive neuronal cytoplasmic inclusions to severe involvement
when nearly all granule cells appeared to contain an inclusion. It is
of note that cases with high numbers of the p62-positive hippo-
campal inclusions also tended to have frequent p62-positive inclu-
sions in the cerebellar granule cells.
Discussion
Here we present a detailed clinical, neuroanatomical and
neuropathological analysis of a series of 19 cases with FTLD and
the C9ORF72 hexanucleotide repeat expansion representing
18 families in the UK. We conﬁrm initial reports (Dejesus-
Hernandez et al., 2011; Gijselinck et al., 2011; Renton et al.,
2011) that this mutation is an important cause of FTLD and
FTLD–MND overlap syndromes, representing 7% of our entire
FTLD series, 8% of FTLD not otherwise accounted for by previ-
ously identiﬁed mutations, 35% of mutation-associated FTLD,
36% of FTLD with clinical evidence of MND and 4% of appar-
ently sporadic FTLD. Identiﬁcation of the C9ORF72 mutation has
allowed attribution of a speciﬁc genetic cause in 88% of all cases
of autosomal dominant FTLD in this series. However, some 33%
of C9ORF72 mutation cases in this series had no known family
history of FTLD or MND. In line with previous evidence in
chromosome 9-linked FTLD and FTD–MND, age at onset (43–68
years), clinical duration (1.6 to 422 years) and clinical features
were highly variable between and within families. The most
common presenting syndrome was behavioural variant FTD,
though around half of cases had an alternative syndrome at pres-
entation, and over the course of follow-up 60% of cases mani-
fested at least some clinical features of MND. This substantial
clinical heterogeneity is in line with previous reports describing
chromosome 9-linked FTLD (Momeni et al., 2006; Morita et al.,
2006; Vance et al., 2006; Valdmanis et al., 2007; Luty et al.,
2008; Le Ber et al., 2009; Gijselinck et al., 2010;
Boxer et al., 2011; Pearson et al., 2011), and was reﬂected in
a range of proﬁles of atrophy distribution and severity on neuroi-
maging of individual patients here. However, group-wise ana-
lyses comparing the C9ORF72 mutation cases with healthy
controls and with other mutation groups suggested certain
common features that may constitute a core phenotype of this
mutation.
Figure 6 Individual brain volumes corrected for total intracra-
nial volume (TIV) by group (top). Annualized percentage change
in brain boundary shift integral (BBSI) by group (middle).
Hemispheric asymmetry expressed as the ratio of left/right
hemisphere volumes by subject and group (bottom).
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inent in a substantial proportion of our C9ORF72 mutation cohort.
These features were of sufﬁcient signiﬁcance here to lead to early
contact with psychiatric services in several cases and a presumptive
diagnosis of encephalitis in one case; it is possible that similar
but less severe symptoms were exhibited by other cases but
were de-emphasized in the context of other behavioural and
cognitive deﬁcits (a limitation of retrospective analyses).
Neuropsychologically, alongside executive dysfunction, deﬁcits of
episodic memory were salient. Indeed, memory impairment
dominated the clinical presentation in several cases, leading to
an initial clinical diagnosis of Alzheimer’s disease in two patients.
Several previous detailed phenomenological and neuropsycho-
logical studies of FTLD have included patients presenting with
prominent neuropsychiatric features (Omar et al., 2009; Lillo
et al., 2010; Loy et al., 2010) or episodic memory impairment
(Hornberger et al., 2010), raising the possibility that apparently
sporadic cases of behavioural variant FTD sharing such phenotypic
features may carry the C9ORF72 repeat expansion. Dominant par-
ietal lobe deﬁcits (acalculia, apraxia) were frequent in the present
Figure 7 (A) Proﬁles of grey matter (GM) atrophy (n = 11) and increased radial diffusivity (RD) maps (n =3 )i nC9ORF72 cases versus
healthy controls. MNI co-ordinates are displayed. (B) Mean difference in cortical thickness expressed as a percentage of the mean
thickness in C9ORF72 cases (n = 11) versus controls. A = anterior; FDR = false discovery rate; FWE = family-wise error; L = left;
P = posterior.
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lobe involvement was previously also found to be a common fea-
ture of GRN mutations (Rohrer et al., 2008). Previous clinical
series of chromosome 9-associated FTLD and FTD–MND have re-
ported similar ﬁndings, with initial neuropsychiatric contact in a
number of cases and clinical diagnoses including Alzheimer’s
disease and corticobasal degeneration (Morita et al., 2006; Luty
et al., 2008; Lillo et al., 2010; Boxer et al., 2011; Murray et al.,
2011; Pearson et al., 2011).
The group-wise neuroanatomical analyses here suggest candi-
date brain substrates for these clinical features. The C9ORF72
mutation group showed extensive cortical loss involving frontal,
Figure 8 Top: Voxel-based morphometry (VBM) proﬁles of grey matter (GM) atrophy by genetic subtype; P50.001. MNI co-ordinates
are displayed. Middle: regional reduction of cortical thickness in MAPT mutation carriers compared with C9ORF72 mutation carriers.
Colour scale for statistical difference represents FDR-corrected P50.05. Bottom: regional variation of cortical thickness in GRN mutation
carriers compared with C9ORF72 mutation carriers. Colour bar for per cent difference represents magnitude of cortical thickness group
difference expressed as a percentage of the mean group thickness. Red and yellow (positive values) represent lower cortical thickness in
the GRN group, whereas dark to light blue (negative values) represent lower cortical thickness in the C9ORF72 group. A = anterior;
FDR = false discovery rate; L = left; P = posterior; Ucorr = uncorrected.
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cerebral hemispheres; while the voxel-based morphometry analysis
showed grey matter loss in thalamus and cerebellum, and tracto-
graphy demonstrated associated damage involving long subcor-
tical projection pathways in the superior and inferior longitudinal
fasciculi, cingulum, thalamic radiations and descending corticosp-
inal tract, as well as the corpus callosum. The atrophy proﬁle of
C9ORF72 mutation cases contrasts both with the relatively loca-
lized temporal lobe involvement associated with MAPT mutation
cases and the strongly asymmetric proﬁle in GRN cases. We
speculate that the relatively sparse cortical correlates shown in
the voxel-based morphometry analysis of the C9ORF72 mutation
cohort here may reﬂect wide inter-subject variation in cortical loss,
with the more consistent involvement of subcortical grey matter
structures (including thalamus and cerebellum) being a more
robust signature of this mutation. We do not argue that the
neuroanatomical signature of the C9ORF72 repeat expansion is
restricted to these regions; subcortical structures typically act as
hubs within structural and functional networks (Van der Werf
et al., 2003; Schmahmann and Pandya, 2008; Tedesco et al.,
2011), with projection targets that include other sites of patho-
logical involvement (for example, the thalamus participates in a
diencephalic network that also includes the hippocampi). The dif-
fuse projections of these subcortical structures may account for the
wide range of cognitive ﬁndings and cortical damage exhibited
across the C9ORF72 mutation cohort here. Involvement of thal-
amus and cerebellar connections could underpin the prominent
neuropsychiatric features shown by these cases (Andreasen
et al., 1996; Schmahmann, 2005; Goossens et al., 2007;
Straube et al., 2007; Schmahmann and Pandya, 2008; Tedesco
et al., 2011), as well as episodic memory deﬁcits (Van der Werf
et al., 2003; de Jong et al., 2008) somatic complaints, hallucin-
ations and delusions (Kessler et al., 2009; Tedesco et al., 2011).
Although none of our cases had frank cerebellar ataxia, this has
been described in previous cases of chromosome 9 linked FTLD
(Pearson et al., 2011).
Neuropathological assessment of six cases with the C9ORF72
repeat expansion demonstrated a heterogeneous proﬁle, in that
both FTLD-TDP type A and type B morphological patterns were
represented. Similar histomorphological heterogeneity has been
emphasized in previous neuropathological analyses of C9ORF72
mutation cases (Murray et al., 2011). In addition, all our
C9ORF72 mutation cases had p62-positive neuronal cytoplasmic
inclusions prominently in excess of TDP-43-positive neuronal cyto-
plasmic inclusions in the granule cells of the hippocampal dentate
gyrus and other hippocampal subregions as well as p62-positive,
TDP-43-negative inclusions in cerebellar granule cells. Our ﬁndings
are supported by a recent publication that proposes this pattern of
proteinopathy as pathognomonic for the C9ORF72 hexanucleatide
repeat insertion (Al-Sarraj et al., 2011). The ubiquitin-binding pro-
tein 62 (p62) or sequestosome 1 (like ubiquitin itself) is a common
component of neuronal and glial proteinaceous inclusions in a
range of neurodegenerative diseases including FTLD-TDP. It has
been previously shown in a proportion of cases with FTLD-TDP
that p62 (and, to a lesser extent, ubiquitin) immunohistochemistry
may highlight a larger number of neuronal cytoplasmic inclusions
in the dentate granule cells than are demonstrated on TDP-43
immunohistochemistry and that small dot-like or star-shaped
p62-positve, TDP-43-negative inclusions may be present in the
granule cells of the cerebellar cortex (Pikkarainen et al., 2008;
King et al., 2011). Furthermore, ubiquitin-positive neuronal
cytoplasmic inclusions in cerebellar granule cells have also been
documented in FTD–MND linked to chromosome 9 due to the
C9ORF72 repeat expansion (Dejesus-Hernandez et al., 2011).
The present neuropathological data support the notion that
‘excess’ p62 pathology may be a characteristic feature of the
C9ORF72 repeat expansion. It is noteworthy that the sites of
heavy p62 involvement identiﬁed here, including hippocampi
and cerebellum, are likely to be pathophysiologically relevant
based on clinical and neuroimaging ﬁndings in the present
cohort. Moreover, these ﬁndings corroborate previous neuro-
pathological evidence in other cohorts. However, the origin and
Figure 9 P62 and TDP-43 immunohistochemistry in FTLD-TDP with the C9ORF72 hexanucleotide repeat expansion. Frequent
p62-positive (A) and sparse TDP-43-positive (B, arrow) neuronal cytoplasmic inclusions were present in the granule cells of the dentate
gyrus in a case with the C9ORF72 repeat expansion. Numerous p62-positive neuronal cytoplasmic inclusions were also present in the
cerebellar granule cell (C), which were negative for TDP-43. Scale bars: A =5 0mm; B =3 0mm; C =8 0mm.
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further investigation, including quantitative analysis of p62 depos-
ition within and between brain regions. In addition, the present
series comprised exclusively cases presenting with FTLD; there
may be a stratiﬁcation of histopathological ﬁndings across the
broader phenotypic spectrum of the C9ORF72 mutations, which
also includes cases presenting with MND (Al-Sarraj et al., 2011;
Murray et al., 2011).
In summary, our ﬁndings suggest that clinicians should consider
the C9ORF72 repeat expansion in patients with FTLD, particularly
with clinical evidence (or a family history) of MND or with prom-
inent anxiety or memory impairment. From a neurobiological per-
spective, our data suggest that involvement of a subcortical
network may underpin the wide-ranging phenotypic features of
the C9ORF72 repeat expansion. Recent clinico-anatomico-
pathological evidence in FTLD suggests that phenotypes arise
from an interaction of molecular and network-speciﬁc factors
(Schmahmann and Pandya, 2008; Rohrer et al., 2011). This hy-
pothesis could be tested speciﬁcally in C9ORF72 mutation cases
by targeting potentially relevant cognitive operations and network
anatomy (Tedesco et al., 2011). Neuropathologically, excess p62
deposition within the culprit network may be a signature of the
C9ORF72 mutation. Future work should analyse these cases pro-
spectively and in relation to other mutation groups, with joint
longitudinal behavioural and neuroimaging (including
connectivity-based) methods, and detailed genotypic stratiﬁcation
and histopathological correlation.
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